New FDA-Approved Treatment for RKD

The FDA has approved Gazyva® (obinutuzumab) for adults and children ages 2 and older with idiopathic nephrotic syndrome that began in childhood and is frequently relapsing (FRNS) or steroid-dependent (SDNS). More information coming soon. Please visit our Patient Navigation tool for support.

en_US EN
en_US EN es_MX ES

RESOURCES

/

FIND A SPECIALIST

/

CONTACT

Back to Clinical Trials
Home / Managing RKD / Clinical Trials /

Trial Currently Unavailable

Sorry, there is no active clinical trial at this location at this time.

Search for Trials Near You
NephCure Logo

INTRO TO RKD

Overview
Types of RKD
Navigating New Diagnosis
Pediatric Care
End-Stage Kidney Disease

SUPPORT

Patient Navigation Services
Online Patient Community
Patient Stories
Support Groups
Resources

MANAGING RKD

Find a Specialist
Clinical Trials
Treatment Options
RKD & Mental Health
Diet & Nutrition
Genetic Testing

LEGAL

Careers
Privacy Policy
Policies & Disclaimers
Financials

ABOUT US

Our Impact
What We Do
Team
Current Partnerships
News
Contact Us

GET INVOLVED

Volunteer
Events
Advocacy
Find your Local Community
Ways to Give

Our Mission

NephCure’s mission is to ensure that all individuals with rare, protein-spilling kidney disease have equitable access to the care and treatments that offer them the best kidney health outcome possible.

Find Us On

NephCure is a registered non-profit (501c3) tax-exempt charitable organization. EIN # 38-3569922.
© Copyright 2024 NephCure, Inc. All rights reserved worldwide. NephCure, and the logo, are federally registered trademarks of NephCure, Inc.